Development of Vorinostat-Loaded Solid Lipid Nanoparticles to Enhance Pharmacokinetics and Efficacy against Multidrug-Resistant Cancer Cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tuan Hiep Tran | - |
dc.contributor.author | Ramasamy, Thiruganesh | - |
dc.contributor.author | Duy Hieu Truong | - |
dc.contributor.author | Shin, Beom Soo | - |
dc.contributor.author | Choi, Han-Gon | - |
dc.contributor.author | Yong, Chul Soon | - |
dc.contributor.author | Kim, Jong Oh | - |
dc.date.accessioned | 2021-06-22T23:01:52Z | - |
dc.date.available | 2021-06-22T23:01:52Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2014-08 | - |
dc.identifier.issn | 0724-8741 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/22336 | - |
dc.description.abstract | To investigate whether delivery of a histone deacetylase inhibitor, vorinostat (VOR), by using solid lipid nanoparticles (SLNs) enhanced its bioavailability and effects on multidrug-resistant cancer cells. VOR-loaded SLNs (VOR-SLNs) were prepared by hot homogenization using an emulsification-sonication technique, and the formulation parameters were optimized. The cytotoxicity of the optimized formulation was evaluated in cancer cell lines (MCF-7, A549, and MDA-MB-231), and pharmacokinetic parameters were examined following oral and intravenous (IV) administration to rats. VOR-SLNs were spherical, with a narrowly distributed average size of similar to 100 nm, and were physically stable for 3 months. Drug release showed a typical bi-phasic pattern in vitro, and was independent of pH. VOR-SLNs were more cytotoxic than the free drug in both sensitive (MCF-7 and A549) and resistant (MDA-MB-231) cancer cells. Importantly, SLN formulations showed prominent cytotoxicity in MDA-MB-231 cells at low doses, suggesting an ability to effectively counter the P-glycoprotein-related drug efflux pumps. Pharmacokinetic studies clearly demonstrated that VOR-SLNs markedly improved VOR plasma circulation time and decreased its elimination rate constant. The areas under the VOR concentration-time curve produced by oral and IV administration of VOR-SLNs were significantly greater than those produced by free drug administration. These in vivo results clearly highlighted the remarkable potential of SLNs to augment the bioavailability of VOR. VOR-SLNs successfully enhanced the oral bioavailability, circulation half-life, and chemotherapeutic potential of VOR. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER/PLENUM PUBLISHERS | - |
dc.title | Development of Vorinostat-Loaded Solid Lipid Nanoparticles to Enhance Pharmacokinetics and Efficacy against Multidrug-Resistant Cancer Cells | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Han-Gon | - |
dc.identifier.doi | 10.1007/s11095-014-1300-z | - |
dc.identifier.scopusid | 2-s2.0-84894051072 | - |
dc.identifier.wosid | 000341712400011 | - |
dc.identifier.bibliographicCitation | PHARMACEUTICAL RESEARCH, v.31, no.8, pp.1978 - 1988 | - |
dc.relation.isPartOf | PHARMACEUTICAL RESEARCH | - |
dc.citation.title | PHARMACEUTICAL RESEARCH | - |
dc.citation.volume | 31 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1978 | - |
dc.citation.endPage | 1988 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | HISTONE DEACETYLASE INHIBITORS | - |
dc.subject.keywordPlus | SUBEROYLANILIDE HYDROXAMIC ACID | - |
dc.subject.keywordPlus | PHYSICOCHEMICAL CHARACTERIZATION | - |
dc.subject.keywordPlus | IMPROVE ENCAPSULATION | - |
dc.subject.keywordPlus | FORMULATION | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | CARRIERS | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | SLN | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordAuthor | Bioavailability | - |
dc.subject.keywordAuthor | Drug resistance | - |
dc.subject.keywordAuthor | Pharmacokinetics | - |
dc.subject.keywordAuthor | Solid lipid nanoparticle | - |
dc.subject.keywordAuthor | Vorinostat | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs11095-014-1300-z | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.